216:, who was awarded the Nobel prize in 2006 for his discovery of RNAi, with the intent to develop RNAi therapies. The company was originally named RXi Pharmaceuticals. RXi went public and in 2009 the company filed a patent for its unique INTASYL technology, a self-delivering RNAi platform. RXi focused on the discovery of RNAi applications for dermatological and ocular therapies. In 2017, after a number of clinical trials that demonstrated safety and clinical efficacy in these areas, the company made the decision to focus on immuno-oncology therapies, with the belief that INTASYL could provide the most value in this application. The company’s name was changed to Phio Pharmaceuticals in November 2018 to reflect its transition from a platform company to one committed to discovering immuno-oncology therapeutics based on its self-delivering RNAi platform.
22:
447:
Byrne M; Tzekov R; Wang Y; Rodgers A; Cardia J; Ford G; Holton K; Pandarinathan L; Lapierre J; Stanney W; Bulock K; Shaw S; Libertine L; Fettes K; Khvorova A; Kaushal S; Pavco P. (December 1, 2013). "Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in
251:
The INTASYL compounds are constructed using a single-stranded phosphorothioate region, a short duplex region, and a variety of nuclease-stabilizing and lipophilic chemical modifications. The result is spontaneous uptake in multiple cell types
336:
239:
Phio's technology platform (INTASYL) allows the development of 'self-delivering’ RNAi compounds, or 'sd-rxRNA' for short, in which drug-like properties were built into the RNAi compound itself, rather than relying on
337:
https://markets.businessinsider.com/news/stocks/phio-announces-new-appointments-to-leadership-team-reports-on-third-quarter-2022-financial-results-and-provides-business-update-1031900693
55:
489:
494:
398:
Lapierre J, Salomon W, Cardia J, Bulock K, Lam JT, Stanney WJ, Ford G, Smith-Anzures B, Woolf T, Kamens J, Khvorova A, Samarsky D (June 1, 2011).
277:
41:
73:
324:
224:
164:
51:
231:. In September 2022 Bitterman was appointed Executive Chair and assumed the duties of Principal Executive Officer.
220:
151:
37:
32:
168:
244:
delivery to improve circulation time and cellular uptake. This platform was developed through systematic
204:. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.
201:
351:"Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC"
245:
465:
429:
380:
325:
https://seekingalpha.com/news/3410790-rxi-pharmaceuticals-changes-name-to-phio-pharmaceuticals
228:
457:
419:
411:
370:
362:
312:
424:
399:
375:
350:
95:
483:
400:"Potent and systematic RNAi mediated silencing with single oligonucleotide compounds"
219:
Phio
Pharmaceuticals stock is traded on Nasdaq as PHIO. The firm is headquartered in
197:
123:
113:
103:
300:
213:
21:
248:
screening and they have shown the utility of their platform in three papers.
349:
Salomon W, Bulock K, Lapierre J, Pavco P, Woolf T, Kamens J (June 1, 2010).
469:
433:
384:
461:
366:
241:
415:
227:. The firm's Chairman is Robert Bitterman, previously an executive at
109:
278:"After name change, Phio Pharma 'reinvents' gene-silencing pipeline"
15:
180:
313:
https://www.wbjournal.com/article/rxi-ipo-moving-forward
47:
175:
157:
147:
129:
119:
101:
91:
301:https://www.britannica.com/biography/Craig-Mello
36:, potentially preventing the article from being
8:
490:Biotechnology companies of the United States
86:
85:
56:reliable, independent, third-party sources
423:
374:
74:Learn how and when to remove this message
50:by replacing them with more appropriate
269:
33:too closely associated with the subject
339:Nov. 10, 2022. Retrieved Dec. 20, 2022
327:Nov. 19. 2018. Retrieved Dec. 20, 2022
315:Feb. 15, 2008. Retrieved Dec. 20, 2022
212:Phio was co-founded by Nobel Laureate
7:
14:
200:company focused on the field of
31:may rely excessively on sources
20:
495:Companies listed on the Nasdaq
1:
135:; 13 years ago
511:
303:. Retrieved Dec. 20, 2022
194:Phio Pharmaceuticals Inc.
87:Phio Pharmaceuticals Inc.
462:10.1089/jop.2013.0148
450:J Ocul Pharmacol Ther
416:10.1261/rna.2399411
282:www.bizjournals.com
246:medicinal chemistry
88:
367:10.1093/nar/gkq055
163:Robert Bitterman (
355:Nucleic Acids Res
191:
190:
84:
83:
76:
502:
474:
473:
444:
438:
437:
427:
395:
389:
388:
378:
346:
340:
334:
328:
322:
316:
310:
304:
298:
292:
291:
289:
288:
274:
225:Middlesex County
221:Marlborough, Ma.
187:
184:
182:
152:Marlborough, Ma.
143:
141:
136:
89:
79:
72:
68:
65:
59:
24:
16:
510:
509:
505:
504:
503:
501:
500:
499:
480:
479:
478:
477:
446:
445:
441:
397:
396:
392:
348:
347:
343:
335:
331:
323:
319:
311:
307:
299:
295:
286:
284:
276:
275:
271:
266:
237:
210:
179:
160:
139:
137:
134:
106:
80:
69:
63:
60:
45:
25:
12:
11:
5:
508:
506:
498:
497:
492:
482:
481:
476:
475:
456:(10): 855–64.
439:
390:
361:(11): 3771–9.
341:
329:
317:
305:
293:
268:
267:
265:
262:
236:
233:
209:
206:
189:
188:
177:
173:
172:
161:
158:
155:
154:
149:
145:
144:
131:
127:
126:
121:
117:
116:
107:
102:
99:
98:
93:
82:
81:
28:
26:
19:
13:
10:
9:
6:
4:
3:
2:
507:
496:
493:
491:
488:
487:
485:
471:
467:
463:
459:
455:
451:
443:
440:
435:
431:
426:
421:
417:
413:
410:(6): 1032–7.
409:
405:
401:
394:
391:
386:
382:
377:
372:
368:
364:
360:
356:
352:
345:
342:
338:
333:
330:
326:
321:
318:
314:
309:
306:
302:
297:
294:
283:
279:
273:
270:
263:
261:
259:
255:
249:
247:
243:
234:
232:
230:
226:
222:
217:
215:
207:
205:
203:
199:
198:biotechnology
195:
186:
178:
174:
170:
166:
162:
156:
153:
150:
146:
132:
128:
125:
124:Biotechnology
122:
118:
115:
111:
108:
105:
100:
97:
94:
90:
78:
75:
67:
57:
53:
49:
43:
39:
35:
34:
29:This article
27:
23:
18:
17:
453:
449:
442:
407:
403:
393:
358:
354:
344:
332:
320:
308:
296:
285:. Retrieved
281:
272:
257:
253:
250:
238:
218:
211:
193:
192:
148:Headquarters
92:Company type
70:
64:January 2016
61:
46:Please help
30:
214:Craig Mello
183:.phiopharma
484:Categories
448:the eye".
287:2022-04-13
264:References
208:Background
159:Key people
48:improve it
38:verifiable
242:liposomal
165:president
104:Traded as
52:citations
470:24180627
434:21493786
385:20167638
254:in vitro
235:Products
196:is a US
120:Industry
425:3096035
376:2887946
258:in vivo
229:Cutanea
176:Website
138: (
130:Founded
112::
42:neutral
468:
432:
422:
383:
373:
110:Nasdaq
96:Public
202:siRNA
466:PMID
430:PMID
381:PMID
256:and
185:.com
167:and
140:2011
133:2011
114:PHIO
40:and
458:doi
420:PMC
412:doi
404:RNA
371:PMC
363:doi
223:in
181:www
169:CEO
54:to
486::
464:.
454:29
452:.
428:.
418:.
408:17
406:.
402:.
379:.
369:.
359:38
357:.
353:.
280:.
260:.
472:.
460::
436:.
414::
387:.
365::
290:.
171:)
142:)
77:)
71:(
66:)
62:(
58:.
44:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
